A Phase 3 interventional study of Rabies vaccine and Rabies vaccines + Rabies immunoglobulins in Rabies Infection, sponsored by Novartis. Completed at 6 sites in 2 countries. Open to participants aged 1 Year and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2017-04-07.
Sponsored by Novartis · Phase 3, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Demonstrate non-inferiority of the immune response between new versus the currently recommended intradermal regimens of rabies vaccine when administered with or without rabies immunoglobulins in healthy subjects ≥ 1 years of age.
115 studies on the registry are indexed under Rabies; 12 are open to participants now.
This study's enrollment of 885 is above the median of 200 across 105 interventional studies indexed under Rabies.
Browse Rabies studies →Novartis is the lead sponsor of 714 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Live vaccines
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
PCEC rabies vaccine, administered ID according to the "4-sites, 1-week" regimen
Biological: Rabies vaccine
PCEC rabies vaccine, administered ID to adults, according to the "4-sites, 1-week" regimen plus HRIG
Biological: Rabies vaccines + Rabies immunoglobulins
PCEC rabies vaccine, administered ID according to the "2-sites, TRC" regimen
Biological: Rabies vaccine
PCEC rabies vaccine, administered ID to adults , according to the "2-sites, TRC" regimen plus HRIG
Biological: Rabies vaccines + Rabies immunoglobulins
12 doses of the PCEC rabies vaccine, administered ID (0.1mL for each injection) according to the "4-sites, 1-week" regimen (i.e. 4 doses of vaccine; in both deltoids and anterolateral thigh areas, administered on days 1, 4, and 8).
12 doses of the PCEC rabies vaccine, administered ID (0.1mL for each injection) to adults only, according to the "4-sites, 1-week" regimen (i.e. 4 doses of vaccine; in both deltoids and anterolateral thigh areas, administered on days 1, 4, and 8). HRIG will be administered on day 1 (before the first dose of the vaccine) in a dose of 20 IU/kg body weight intramuscularly into the gluteal muscle.
8 doses of the PCEC rabies vaccine, administered ID (0.1ml for each injection) according to the "2-sites, TRC", updated Thai Red Cross regimen (i.e. 2 doses of vaccine; in both deltoids, administered on days 1, 4, 8, and 29).
8 doses of the PCEC rabies vaccine, administered ID (0.1ml for each injection) to adults only, according to the "2-sites, TRC", updated Thai Red Cross regimen (i.e. 2 doses of vaccine; in both deltoids, administered on days 1, 4, 8, and 29). HRIG will be administered on day 1 (before the first dose of the vaccine) in a dose of 20 IU/kg body weight intramuscularly into the gluteal muscle.
Percentages of Subjects With RVNA Titer >= 0.5 and Vaccine Group Differences ("4-sites, 1-week" to That of "2-sites, TRC" ID PEP Regimen of the PCEC Rabies Vaccine With or Without HRIG Administration)
Vaccine group differences are calculated assuming a binomial distribution and the associated confidence interval for the differences in percentage was based on M-N method. Non-inferiority of the immune response of the new "4-sites, 1-week" ID PEP regimen of the PCEC vaccine, with or without HRIG administration, to that of the currently recommended "2-sites, TRC" ID PEP regimen of the PCEC rabies vaccine with or without HRIG administration, as measured by the percentage of subjects with RVNA titer ≥ 0.5 IU/ml at day 50 in the whole study population.
Time frame: Study day 50 (D50)
Geometric Mean Rabies Virus Neutralizing Antibody (RVNA) Concentration and Between-group (2 ID Rabies Vaccine Regimens (4-sites, 1-week and 2-sites, TRC) With or Without HRIG) Ratio of GMCs
Immunogenicity was assessed in terms of Geometric Mean Rabies Virus Neutralizing Antibody (RVNA) Concentration in Children and Adult Subjects, ≥ 1 Years of Age at day 50 The GMCs, GMRs (i.e., within group ratio) and associated two sided 95% confidence intervals for each group were computed by exponentiating (base 10) of the least square means of the logarithmically transformed (base 10) concentration (and their differences) and the 95% CIs obtained from an Analysis of variance (ANOVA) with vaccine regimen, age strata and center as factors. Non-inferiority of the immune response between the 2 ID rabies vaccine regimens (4-sites, 1-week and 2-sites, TRC) with or without HRIG administration as measured by RVNA GMCs at day 50 in the whole study population.
Time frame: Study Day 50
Geometric Mean Rabies Virus Neutralizing Antibody Concentration at Days 8, 15, 91, 181 and 366 & Between-group (2 ID Rabies Vaccine Regimens (4-sites,1-week & 2-sites, TRC) With or Without HRIG) Ratio of GMCs in Children & Adult Subjects,≥ 1 Years of Age
Immunogenicity was assessed in terms of the Geometric Mean Rabies Virus Neutralizing Antibody (RVNA) Concentration at Days 8, 15, 91, 181 and 366 in Children and Adult Subjects, ≥ 1 Years of Age The GMCs, GMRs (i.e., within group ratio) and associated two sided 95% confidence intervals for each group were computed by exponentiating (base 10) of the least square means of the logarithmically transformed (base 10) concentration (and their differences) and the 95% CIs obtained from an Analysis of variance (ANOVA) with vaccine regimen, age strata and center as factors. Non-inferiority of the immune response between the 2 ID rabies vaccine regimens (4-sites, 1-week and 2-sites, TRC) with or without HRIG administration as measured by RVNA GMCs at day 50 in the whole study population.
Time frame: At Days 8, 15, 91, 181 and 366
Percentages of Subjects With Anti-RVNA Titer ≥0.5 IU/mL at Days 8, 15, 91, 181 and 366 in Children and Adult Subjects and Vaccine Group Differences (2 ID Rabies Vaccine Regimens (4-sites, 1-week and 2-sites, TRC), With or Without HRIG), ≥ 1 Years of Age
Vaccine group differences are calculated assuming a binomial distribution and the associated confidence interval for the differences in percentage was based on M-N method. RVNA percentage of subjects with RVNA titer ≥ 0.5 IU/mL at study days 8, 15, 91, 181, and 366 following administration of the 2 ID rabies vaccine regimens (4-sites, 1-week and 2-sites, TRC), with or without HRIG, in the whole study population.
Time frame: At Days 8, 15, 91, 181 and 366
Geometric Mean Rabies Virus Neutralizing Antibody (RVNA) Concentration and Vaccine Group Differences in Adult Subjects, ≥ 18 Years of Age
Immunogenicity was assessed in terms of the Geometric Mean Rabies Virus Neutralizing Antibody (RVNA) Concentration at Days 8, 15, 50,91, 181 and 366 in Adult Subjects, ≥ 18 Years of Age. RVNA GMCs with RVNA titer ≥ 0.5 IU/mL at days 8, 15, 50, 91, 181 and 366 and group differences (4-sites,1-week without HRIG versus 4-sites,1-week with HRIG; 4-sites,1-week with HRIG versus 2-sites,TRC with HRIG; 4-sites,1-week without HRIG versus 2-sites, TRC without HRIG)
Time frame: At Days 8, 15, 50, 91, 181 and 366
Percentages of Subjects With Anti-RVNA Titer ≥0.5 IU/mL in Adult Subjects, ≥ 18 Years of Age
Immunogenicity was assessed in terms of the Percentages of Subjects With Anti-RVNA concentration ≥0.5 IU/mL at Days 8, 15, 50, 91, 181 and 366 in Adult Subjects, ≥ 18 Years of Age. Percentage of subjects with RVNA titer ≥ 0.5 IU/mL at days 8, 15, 50, 91, 181 and 366 and group differences (4-sites,1-week without HRIG versus 4-sites,1-week with HRIG; 4-sites,1-week with HRIG versus 2-sites,TRC with HRIG; 4-sites,1-week without HRIG versus 2-sites, TRC without HRIG)
Time frame: At Days 8, 15,50, 91, 181 and 366
Geometric Mean Rabies Virus Neutralizing Antibody (RVNA) Concentration in Children and Adult Subjects, ≥ 1 Years of Age
Immunogenicity was assessed in terms of the Geometric Mean Rabies Virus Neutralizing Antibody (RVNA) Concentration at Days 8, 15, 50, 91, 181 and 366 in Children and Adult Subjects, ≥ 1 Years of Age
Time frame: At Days 8, 15, 50, 91, 181 and 366
Percentages of Subjects With Anti-RVNA Titer ≥0.5 IU/mL in Children and Adult Subjects, ≥ 1 Years of Age
Immunogenicity was assessed in terms of the Percentages of Subjects With Anti-RVNA concentration ≥0.5 IU/mL at Days 8, 15, 50, 91, 181 and 366 in Children and Adult Subjects, ≥ 1 Years of Age
Time frame: At Days 8, 15, 50, 91, 181 and 366
Number of Subjects Who Reported Solicited Local and Systemic Adverse Events After Any Vaccination
Number of subjects Who Reported Solicited Local and Systemic Adverse Events After Any Vaccination
Time frame: From day 1 to day 3; from day 4 to day 7; from day 8 to day 14; from day 29 to day 35(2-sites, TRC PEP, ID regimen)
Number of Subjects Reporting Unsolicited Adverse Events (AEs)
Safety was assessed in terms of the Number of Subjects Reporting Unsolicited Adverse Events (AEs)
Time frame: Day 1 to Day 366
Geometric Mean Rabies Virus Neutralizing Antibody (RVNA) Concentration ≥0.5 IU/mL and Vaccine Group Differences in Adult Subjects, ≥ 18 Years of Age
Immunogenicity was assessed in terms of the Geometric Mean Rabies Virus Neutralizing Antibody (RVNA) Concentration ≥0.5 IU/mL at Days 8, 15, 50,91, 181 and 366 in Adult Subjects, ≥ 18 Years of Age
Time frame: At Days 8, 15, 50, 91, 181 and 366
Percentages of Subjects With Anti-RVNA Titer ≥0.5 IU/mL in Adult Subjects, ≥ 18 Years of Age
Immunogenicity was assessed in terms of the number of subjects With Anti-RVNA concentration ≥0.5 IU/mL at Days 8, 15, 50, 91, 181 and 366 in Adult Subjects, ≥ 18 Years of Age
Time frame: At Days 8, 15,50, 91, 181 and 366
| Milestone | 4-sites, 1-week WITHOUT HRIG | 4-sites, 1-week WITH HRIG | 2-sites, TRC WITHOUT HRIG | 2-sites, TRC WITH HRIG |
|---|---|---|---|---|
| Started | 355 | 88 | 354 | 88 |
| Completed | 350 | 86 | 351 | 88 |
| Not completed | 5 | 2 | 3 | 0 |
| Withdrew: Administrative reason | 2 | 0 | 1 | 0 |
| Withdrew: Lost to follow-up | 0 | 2 | 0 | 0 |
| Withdrew: Other | 2 | 0 | 1 | 0 |
| Withdrew: Withdrawal by subject | 1 | 0 | 1 | 0 |
Vaccine group differences are calculated assuming a binomial distribution and the associated confidence interval for the differences in percentage was based on M-N method. Non-inferiority of the immune response of the new "4-sites, 1-week" ID PEP regimen of the PCEC vaccine, with or without HRIG administration, to that of the currently recommended "2-sites, TRC" ID PEP regimen of the PCEC rabies vaccine with or without HRIG administration, as measured by the percentage of subjects with RVNA titer ≥ 0.5 IU/ml at day 50 in the whole study population.
| Percentages of Subjects | TOTAL 4-sites, 1-week | TOTAL 2-sites, TRC |
|---|---|---|
| Percentages of Subjects With RVNA Titer >= 0.5 and Vaccine Group Differences ("4-sites, 1-week" to That of "2-sites, TRC" ID PEP Regimen of the PCEC Rabies Vaccine With or Without HRIG Administration) | 99 (98 to 100) | 100 (99 to 100) |
Immunogenicity was assessed in terms of Geometric Mean Rabies Virus Neutralizing Antibody (RVNA) Concentration in Children and Adult Subjects, ≥ 1 Years of Age at day 50 The GMCs, GMRs (i.e., within group ratio) and associated two sided 95% confidence intervals for each group were computed by exponentiating (base 10) of the least square means of the logarithmically transformed (base 10) concentration (and their differences) and the 95% CIs obtained from an Analysis of variance (ANOVA) with vaccine regimen, age strata and center as factors. Non-inferiority of the immune response between the 2 ID rabies vaccine regimens (4-sites, 1-week and 2-sites, TRC) with or without HRIG administration as measured by RVNA GMCs at day 50 in the whole study population.
| IU/mL | TOTAL 4-sites, 1-week | TOTAL 2-sites, TRC |
|---|---|---|
| Geometric Mean Rabies Virus Neutralizing Antibody (RVNA) Concentration and Between-group (2 ID Rabies Vaccine Regimens (4-sites, 1-week and 2-sites, TRC) With or Without HRIG) Ratio of GMCs | 4.58 (4.15 to 5.06) | 10 (9.29 to 11) |
Immunogenicity was assessed in terms of the Geometric Mean Rabies Virus Neutralizing Antibody (RVNA) Concentration at Days 8, 15, 91, 181 and 366 in Children and Adult Subjects, ≥ 1 Years of Age The GMCs, GMRs (i.e., within group ratio) and associated two sided 95% confidence intervals for each group were computed by exponentiating (base 10) of the least square means of the logarithmically transformed (base 10) concentration (and their differences) and the 95% CIs obtained from an Analysis of variance (ANOVA) with vaccine regimen, age strata and center as factors. Non-inferiority of the immune response between the 2 ID rabies vaccine regimens (4-sites, 1-week and 2-sites, TRC) with or without HRIG administration as measured by RVNA GMCs at day 50 in the whole study population.
| IU/mL | TOTAL 4-sites, 1-week | TOTAL 2-sites, TRC |
|---|---|---|
| Day 8 (N= 363, 362) | 0.23 (0.21 to 0.25) | 0.14 (0.13 to 0.15) |
| Day 15 (N= 357, 361) | 18 (17 to 20) | 12 (10 to 13) |
| Day 91 (N= 358, 362) | 2.32 (2.09 to 2.56) | 3.68 (3.32 to 4.07) |
| Day 181 (N= 357, 360) | 1.59 (1.41 to 1.78) | 1.44 (1.28 to 1.62) |
| Day 366 (N= 356, 352) | 1.59 (1.41 to 1.79) | 1.14 (1.01 to 1.28) |
Vaccine group differences are calculated assuming a binomial distribution and the associated confidence interval for the differences in percentage was based on M-N method. RVNA percentage of subjects with RVNA titer ≥ 0.5 IU/mL at study days 8, 15, 91, 181, and 366 following administration of the 2 ID rabies vaccine regimens (4-sites, 1-week and 2-sites, TRC), with or without HRIG, in the whole study population.
| Percentages of Subjects | TOTAL 4-sites, 1-week | TOTAL 2-sites, TRC |
|---|---|---|
| Day 8 (N= 363, 362) | 18 (15 to 23) | 10 (7 to 13) |
| Day 15 (N= 357, 361) | 100 (99 to 100) | 100 (98 to 100) |
| Day 91 (N= 358, 362) | 96 (94 to 98) | 99 (98 to 100) |
| Day 181 (N= 357, 360) | 93 (90 to 95) | 93 (90 to 96) |
| Day 366 (N= 356, 352) | 90 (86 to 93) | 83 (79 to 87) |
Immunogenicity was assessed in terms of the Geometric Mean Rabies Virus Neutralizing Antibody (RVNA) Concentration at Days 8, 15, 50,91, 181 and 366 in Adult Subjects, ≥ 18 Years of Age. RVNA GMCs with RVNA titer ≥ 0.5 IU/mL at days 8, 15, 50, 91, 181 and 366 and group differences (4-sites,1-week without HRIG versus 4-sites,1-week with HRIG; 4-sites,1-week with HRIG versus 2-sites,TRC with HRIG; 4-sites,1-week without HRIG versus 2-sites, TRC without HRIG)
| IU/mL | 4-sites, 1-week WITH HRIG | 4-sites, 1-week WITHOUT HRIG |
|---|---|---|
| Day 8 (N= 66, 150) | 0.21 (0.17 to 0.26) | 0.15 (0.13 to 0.17) |
| Day 15 (N= 65, 146) | 13 (11 to 15) | 15 (13 to 17) |
| Day 50 (N= 65, 146) | 1.97 (1.6 to 2.43) | 4.47 (3.9 to 5.13) |
| Day 91 (N= 65, 149) | 1.01 (0.81 to 1.27) | 2.28 (1.96 to 2.65) |
| Day 181 (N= 65, 146) | 0.88 (0.67 to 1.14) | 1.92 (1.61 to 2.29) |
| Day 366 (N= 65, 145) | 0.68 (0.53 to 0.88) | 1.42 (1.19 to 1.69) |
Immunogenicity was assessed in terms of the Percentages of Subjects With Anti-RVNA concentration ≥0.5 IU/mL at Days 8, 15, 50, 91, 181 and 366 in Adult Subjects, ≥ 18 Years of Age. Percentage of subjects with RVNA titer ≥ 0.5 IU/mL at days 8, 15, 50, 91, 181 and 366 and group differences (4-sites,1-week without HRIG versus 4-sites,1-week with HRIG; 4-sites,1-week with HRIG versus 2-sites,TRC with HRIG; 4-sites,1-week without HRIG versus 2-sites, TRC without HRIG)
| Percentages of Subjects | 4-sites, 1-week WITH HRIG | 4-sites, 1-week WITHOUT HRIG |
|---|---|---|
| Day 1 (N= 66, 151) | 0 (0 to 5) | 0 (0 to 2) |
| Day 8 (N= 66, 150) | 8 (3 to 17) | 19 (13 to 26) |
| Day 15 (N= 65, 146) | 100 (94 to 100) | 100 (98 to 100) |
| Day 50 (N= 65, 146) | 95 (87 to 99) | 100 (98 to 100) |
| Day 91 (N= 65, 149) | 83 (72 to 91) | 98 (94 to 100) |
| Day 181 (N= 65, 146) | 77 (65 to 86) | 94 (89 to 97) |
| Day 366 (N= 65, 145) | 66 (53 to 77) | 91 (85 to 95) |
Immunogenicity was assessed in terms of the Geometric Mean Rabies Virus Neutralizing Antibody (RVNA) Concentration at Days 8, 15, 50, 91, 181 and 366 in Children and Adult Subjects, ≥ 1 Years of Age
| IU/mL | 4-sites, 1-week Without HRIG | 2-sites, TRC Without HRIG |
|---|---|---|
| Day 1 (N=298, 290) | 0.05 (0.05 to 0.05) | 0.05 (0.05 to 0.05) |
| Day 8 (N= 297, 290) | 0.23 (0.21 to 0.25) | 0.13 (0.12 to 0.14) |
| Day 15 (N= 292, 289) | 19 (17 to 21) | 12 (11 to 13) |
| Day 50 (N= 292, 281) | 5.04 (4.56 to 5.57) | 10 (9.48 to 12) |
| Day 91 (N= 293, 290) | 2.54 (2.29 to 2.82) | 3.8 (3.42 to 4.21) |
| Day 181 (N= 292, 289) | 1.73 (1.53 to 1.95) | 1.5 (1.32 to 1.69) |
| Day 366 (N= 291, 283) | 1.73 (1.53 to 1.95) | 1.2 (1.06 to 1.36) |
Immunogenicity was assessed in terms of the Percentages of Subjects With Anti-RVNA concentration ≥0.5 IU/mL at Days 8, 15, 50, 91, 181 and 366 in Children and Adult Subjects, ≥ 1 Years of Age
| Percentages of Subjects | 4-sites, 1-week Without HRIG | 2-sites, TRC Without HRIG |
|---|---|---|
| Day 8 (N= 297, 290) | 21 (16 to 26) | 10 (7 to 14) |
| Day 15 (N= 292, 289) | 100 (99 to 100) | 100 (99 to 100) |
| Day 50 (N= 292, 281) | 100 (99 to 100) | 100 (99 to 100) |
| Day 91 (N= 293, 290) | 99 (97 to 100) | 100 (98 to 100) |
| Day 181 (N= 292, 289) | 96 (93 to 98) | 96 (92 to 98) |
| Day 366 (N= 291, 283) | 95 (92 to 97) | 87 (82 to 90) |
Number of subjects Who Reported Solicited Local and Systemic Adverse Events After Any Vaccination
| Subjects | 4-sites, 1-week WITHOUT HRIG | 4-sites, 1-week WITH HRIG | 2-sites, TRC WITHOUT HRIG | 2-sites, TRC WITH HRIG |
|---|---|---|---|---|
| Injection site erythema(≥ 1 to ≤ 5 Y); Day 1 | 0 | NA | 0 | NA |
| Injection site erythema(≥ 1 to ≤ 5 Y); Day 4 | 0 | NA | 0 | NA |
| Injection site erythema(≥ 1 to ≤ 5 Y); Day 8 | 1 | NA | 0 | NA |
| Injection site erythema(≥ 1 to ≤ 5 Y); Day 29 | NA | NA | 2 | NA |
| Injection site induration(≥ 1 to ≤ 5 Y); Day 1 | 0 | NA | 0 | NA |
| Injection site induration(≥ 1 to ≤ 5 Y); Day 4 | 0 | NA | 0 | NA |
| Injection site induration(≥ 1 to ≤ 5 Y); Day 8 | 0 | NA | 0 | NA |
| Injection site induration(≥ 1 to ≤ 5 Y); Day 29 | NA | NA | 1 | NA |
| Injection site swelling (≥ 1 to ≤ 5 Y); Day 1 | 0 | NA | 0 | NA |
| Injection site swelling (≥ 1 to ≤ 5 Y); Day 4 | 0 | NA | 0 | NA |
| Injection site swelling (≥ 1 to ≤ 5 Y); Day 8 | 0 | NA | 2 | NA |
| Injection site swelling (≥ 1 to ≤ 5 Y); Day 29 | NA | NA | 8 | NA |
| Injection site erythema (≥ 6 to ≤ 17 Y); Day 1 | 0 | NA | 0 | NA |
| Injection site erythema (≥ 6 to ≤ 17 Y); Day 4 | 0 | NA | 0 | NA |
| Injection site erythema (≥ 6 to ≤ 17 Y); Day 8 | 1 | NA | 2 | NA |
| Injection site erythema (≥ 6 to ≤ 17 Y); Day 29 | NA | NA | 8 | NA |
| Injection site induration (≥ 6 to ≤ 17 Y); Day 1 | 0 | NA | 0 | NA |
| Injection site induration (≥ 6 to ≤ 17 Y); Day 4 | 1 | NA | 0 | NA |
| Injection site induration (≥ 6 to ≤ 17 Y); Day 8 | 0 | NA | 1 | NA |
| Injection site induration (≥ 6 to ≤ 17 Y); Day 29 | NA | NA | 2 | NA |
| Injection site swelling (≥ 6 to ≤ 17 Y); Day 1 | 0 | NA | 0 | NA |
| Injection site swelling (≥ 6 to ≤ 17 Y); Day 4 | 1 | NA | 0 | NA |
| Injection site swelling (≥ 6 to ≤ 17 Y); Day 8 | 0 | NA | 2 | NA |
| Injection site swelling (≥ 6 to ≤ 17 Y); Day 29 | NA | NA | 2 | NA |
| Injection site erythema (≥ 18 Y); Day 1 | 3 | 6 | 2 | 3 |
| Injection site erythema (≥ 18 Y); Day 4 | 11 | 4 | 4 | 5 |
| Injection site erythema (≥ 18 Y); Day 8 | 12 | 1 | 8 | 4 |
| Injection site erythema (≥ 18 Y); Day 29 | NA | NA | 27 | 13 |
| Injection site induration (≥ 18 Y); Day 1 | 0 | 0 | 0 | 0 |
| Injection site induration (≥ 18 Y); Day 4 | 0 | 0 | 0 | 0 |
| Injection site induration (≥ 18 Y); Day 8 | 2 | 0 | 2 | 0 |
| Injection site induration (≥ 18 Y); Day 29 | NA | NA | 4 | 1 |
| Injection site swelling (≥ 18 Y); Day 1 | 0 | 0 | 1 | 0 |
| Injection site swelling (≥ 18 Y); Day 4 | 0 | 0 | 0 | 0 |
| Injection site swelling (≥ 18 Y); Day 8 | 0 | 0 | 2 | 0 |
| Injection site swelling (≥ 18 Y); Day 29 | NA | NA | 5 | 1 |
| Change In Eating Habits,( ≥ 1 to ≤ 5 Y); Day 1 | 4 | NA | 3 | NA |
| Change In Eating Habits,( ≥ 1 to ≤ 5 Y); Day 4 | 3 | NA | 1 | NA |
| Change In Eating Habits,( ≥ 1 to ≤ 5 Y); Day 8 | 3 | NA | 2 | NA |
| Change In Eating Habits,( ≥ 1 to ≤ 5 Y); Day 29 | NA | NA | 6 | NA |
| Sleepiness (≥ 1 to ≤ 5 Y); Day 1 | 4 | NA | 7 | NA |
| Sleepiness (≥ 1 to ≤ 5 Y); Day 4 | 7 | NA | 3 | NA |
| Sleepiness (≥ 1 to ≤ 5 Y); Day 8 | 2 | NA | 4 | NA |
| Sleepiness (≥ 1 to ≤ 5 Y); Day 29 | NA | NA | 2 | NA |
| Vomiting (≥ 1 to ≤ 5 Y); Day 1 | 4 | NA | 1 | NA |
| Vomiting (≥ 1 to ≤ 5 Y); Day 4 | 2 | NA | 1 | NA |
| Vomiting (≥ 1 to ≤ 5 Y); Day 8 | 1 | NA | 0 | NA |
| Vomiting (≥ 1 to ≤ 5 Y); Day 29 | NA | NA | 5 | NA |
| Diarrhea (≥ 1 to ≤ 5 Y); Day 1 | 3 | NA | 2 | NA |
| Diarrhea (≥ 1 to ≤ 5 Y); Day 4 | 2 | NA | 2 | NA |
| Diarrhea (≥ 1 to ≤ 5 Y); Day 8 | 4 | NA | 1 | NA |
| Diarrhea (≥ 1 to ≤ 5 Y); Day 29 | NA | NA | 4 | NA |
| Irritability.( ≥ 1 to ≤ 5 Y); Day 1 | 5 | NA | 3 | NA |
| Irritability.( ≥ 1 to ≤ 5 Y); Day 4 | 3 | NA | 3 | NA |
| Irritability.( ≥ 1 to ≤ 5 Y); Day 8 | 1 | NA | 5 | NA |
| Irritability.( ≥ 1 to ≤ 5 Y); Day 29 | NA | NA | 5 | NA |
| Chills(≥ 6 to ≤ 17 Y); Day 1 | 2 | NA | 2 | NA |
| Chills(≥ 6 to ≤ 17 Y); Day 4 | 0 | NA | 1 | NA |
| Chills(≥ 6 to ≤ 17 Y); Day 8 | 1 | NA | 1 | NA |
| Chills(≥ 6 to ≤ 17 Y); Day 29 | NA | NA | 0 | NA |
| Nausea ( ≥ 6 to ≤ 17 Y); Day 1 | 4 | NA | 3 | NA |
| Nausea ( ≥ 6 to ≤ 17 Y); Day 4 | 2 | NA | 1 | NA |
| Nausea ( ≥ 6 to ≤ 17 Y); Day 8 | 3 | NA | 1 | NA |
| Nausea ( ≥ 6 to ≤ 17 Y); Day 29 | NA | NA | 0 | NA |
| Generalized Myalgia (≥ 6 to ≤ 17 Y); Day 1 | 5 | NA | 1 | NA |
| Generalized Myalgia (≥ 6 to ≤ 17 Y); Day 4 | 4 | NA | 2 | NA |
| Generalized Myalgia (≥ 6 to ≤ 17 Y); Day 8 | 2 | NA | 3 | NA |
| Generalized Myalgia (≥ 6 to ≤ 17 Y); Day 29 | NA | NA | 4 | NA |
| Generalized Arthralgia (≥ 6 to ≤ 17 Y); Day 1 | 3 | NA | 1 | NA |
| Generalized Arthralgia (≥ 6 to ≤ 17 Y); Day 4 | 1 | NA | 1 | NA |
| Generalized Arthralgia (≥ 6 to ≤ 17 Y); Day 8 | 4 | NA | 2 | NA |
| Generalized Arthralgia (≥ 6 to ≤ 17 Y); Day 29 | NA | NA | 1 | NA |
| Headache (≥ 6 to ≤ 17 Y); Day 1 | 8 | NA | 9 | NA |
| Headache (≥ 6 to ≤ 17 Y); Day 4 | 8 | NA | 8 | NA |
| Headache (≥ 6 to ≤ 17 Y); Day 8 | 6 | NA | 6 | NA |
| Headache (≥ 6 to ≤ 17 Y); Day 29 | NA | NA | 3 | NA |
| Fatigue (≥ 6 to ≤ 17 Y); Day 1 | 8 | NA | 7 | NA |
| Fatigue (≥ 6 to ≤ 17 Y); Day 4 | 5 | NA | 1 | NA |
| Fatigue (≥ 6 to ≤ 17 Y); Day 8 | 1 | NA | 6 | NA |
| Fatigue (≥ 6 to ≤ 17 Y); Day 29 | NA | NA | 6 | NA |
| Rash (≥ 6 to ≤ 17 Y); Day 1 | 4 | NA | 0 | NA |
| Rash (≥ 6 to ≤ 17 Y); Day 4 | 3 | NA | 3 | NA |
| Rash (≥ 6 to ≤ 17 Y); Day 8 | 3 | NA | 3 | NA |
| Rash (≥ 6 to ≤ 17 Y); Day 29 | NA | NA | 2 | NA |
| Vomitting (≥ 6 to ≤ 17 Y); Day 1 | 3 | NA | 5 | NA |
| Vomitting (≥ 6 to ≤ 17 Y); Day 4 | 2 | NA | 1 | NA |
| Vomitting (≥ 6 to ≤ 17 Y); Day 8 | 3 | NA | 2 | NA |
| Vomitting (≥ 6 to ≤ 17 Y); Day 29 | NA | NA | 1 | NA |
| Diarrhea (≥ 6 to ≤ 17 Y); Day 1 | 4 | NA | 2 | NA |
| Diarrhea (≥ 6 to ≤ 17 Y); Day 4 | 0 | NA | 1 | NA |
| Diarrhea (≥ 6 to ≤ 17 Y); Day 8 | 1 | NA | 0 | NA |
| Diarrhea (≥ 6 to ≤ 17 Y); Day 29 | NA | NA | 0 | NA |
| Loss Of Appetite (≥ 6 to ≤ 17 Y); Day 1 | 6 | NA | 3 | NA |
| Loss Of Appetite (≥ 6 to ≤ 17 Y); Day 4 | 3 | NA | 1 | NA |
| Loss Of Appetite (≥ 6 to ≤ 17 Y); Day 8 | 1 | NA | 1 | NA |
| Loss Of Appetite (≥ 6 to ≤ 17 Y); Day 29 | NA | NA | 0 | NA |
| Chills (≥ 18 Y); Day 1 | 8 | 3 | 5 | 2 |
| Chills (≥ 18 Y); Day 4 | 1 | 2 | 6 | 4 |
| Chills (≥ 18 Y); Day 8 | 5 | 0 | 4 | 0 |
| Chills (≥ 18 Y); Day 29 | NA | NA | 0 | 0 |
| Nausea,( ≥ 18 Y); Day 1 | 8 | 3 | 3 | 3 |
| Nausea,( ≥ 18 Y); Day 4 | 4 | 2 | 2 | 3 |
| Nausea,( ≥ 18 Y); Day 8 | 4 | 0 | 4 | 3 |
| Nausea,( ≥ 18 Y); Day 29 | NA | NA | 0 | 0 |
| Generalized Myalgia (≥ 18 Y); Day 1 | 23 | 12 | 19 | 12 |
| Generalized Myalgia (≥ 18 Y); Day 4 | 16 | 7 | 12 | 6 |
| Generalized Myalgia (≥ 18 Y); Day 8 | 20 | 5 | 15 | 9 |
| Generalized Myalgia (≥ 18 Y); Day 29 | NA | NA | 7 | 4 |
| Generalized Arthralgia (≥ 18 Y); Day 1 | 18 | 7 | 13 | 7 |
| Generalized Arthralgia (≥ 18 Y); Day 4 | 6 | 5 | 10 | 7 |
| Generalized Arthralgia (≥ 18 Y); Day 8 | 15 | 3 | 15 | 6 |
| Generalized Arthralgia (≥ 18 Y); Day 29 | NA | NA | 6 | 4 |
| Headache (≥ 18 Y); Day 1 | 24 | 6 | 11 | 13 |
| Headache (≥ 18 Y); Day 4 | 14 | 10 | 15 | 11 |
| Headache (≥ 18 Y); Day 8 | 19 | 8 | 15 | 16 |
| Headache (≥ 18 Y); Day 29 | NA | NA | 12 | 11 |
| Fatigue (≥ 18 Y); Day 1 | 28 | 11 | 19 | 10 |
| Fatigue (≥ 18 Y); Day 4 | 21 | 6 | 17 | 11 |
| Fatigue (≥ 18 Y); Day 8 | 19 | 8 | 15 | 14 |
| Fatigue (≥ 18 Y); Day 29 | NA | NA | 9 | 10 |
| Rash (≥ 18 Y); Day 1 | 10 | 3 | 4 | 0 |
| Rash (≥ 18 Y); Day 4 | 4 | 3 | 8 | 4 |
| Rash (≥ 18 Y); Day 8 | 6 | 4 | 11 | 2 |
| Rash (≥ 18 Y); Day 29 | NA | NA | 2 | 2 |
| Vomitting (≥ 18 Y); Day 1 | 0 | 0 | 2 | 0 |
| Vomitting (≥ 18 Y); Day 4 | 0 | 1 | 1 | 1 |
| Vomitting (≥ 18 Y); Day 8 | 1 | 0 | 1 | 3 |
| Vomitting (≥ 18 Y); Day 29 | NA | NA | 1 | 0 |
| Diarrhea (≥ 18 Y); Day 1 | 5 | 4 | 2 | 5 |
| Diarrhea (≥ 18 Y); Day 4 | 3 | 2 | 5 | 3 |
| Diarrhea (≥ 18 Y); Day 8 | 5 | 1 | 4 | 4 |
| Diarrhea (≥ 18 Y); Day 29 | NA | NA | 3 | 0 |
| Loss Of Appetite (≥ 18 Y); Day 1 | 7 | 0 | 5 | 2 |
| Loss Of Appetite (≥ 18 Y); Day 4 | 3 | 2 | 2 | 0 |
| Loss Of Appetite (≥ 18 Y); Day 8 | 3 | 3 | 2 | 4 |
| Loss Of Appetite (≥ 18 Y); Day 29 | NA | NA | 1 | 1 |
| Injection site tenderness (≥ 1 to ≤ 5 Y); Day 1 | 15 | NA | 8 | NA |
| Injection site tenderness (≥ 1 to ≤ 5 Y); Day 4 | 8 | NA | 9 | NA |
| Injection site tenderness (≥ 1 to ≤ 5 Y); Day 8 | 7 | NA | 8 | NA |
| Injection site tenderness (≥ 1 to ≤ 5 Y); Day 29 | NA | NA | 9 | NA |
| Injection site pain (≥ 6 to ≤ 17 Y); Day 1 | 14 | NA | 7 | NA |
| Injection site pain (≥ 6 to ≤ 17 Y); Day 4 | 6 | NA | 10 | NA |
| Injection site pain (≥ 6 to ≤ 17 Y); Day 8 | 6 | NA | 11 | NA |
| Injection site pain (≥ 6 to ≤ 17 Y); Day 29 | NA | NA | 6 | NA |
| Injection site pain (≥ 18 Y); Day 1 | 12 | 6 | 16 | 11 |
| Injection site pain (≥ 18 Y); Day 4 | 8 | 8 | 13 | 3 |
| Injection site pain (≥ 18 Y); Day 8 | 8 | 7 | 21 | 3 |
| Injection site pain (≥ 18 Y); Day 29 | NA | NA | 14 | 9 |
Safety was assessed in terms of the Number of Subjects Reporting Unsolicited Adverse Events (AEs)
| Subjects | 4-sites, 1-week WITHOUT HRIG | 4-sites, 1-week WITH HRIG | 2-sites, TRC WITHOUT HRIG | 2-sites, TRC WITH HRIG |
|---|---|---|---|---|
| ≥ 1 to ≤ 5 Y Any AEs;D1-366 | 45 | NA | 53 | NA |
| ≥ 1 to ≤ 5 Y SAE;D1-366 | 3 | NA | 4 | NA |
| ≥ 1 to ≤ 5 Y At least possibly related SAEs;D1-366 | 0 | NA | 0 | NA |
| ≥ 1 to ≤ 5 Y Deaths;D1-366 | 0 | NA | 0 | NA |
| ≥1 to ≤ 5 Y Withdrawal from study due to AE;D1-366 | 0 | NA | 0 | NA |
| ≥ 6 to ≤ 17 Y Any AEs;D1-366 | 58 | NA | 71 | 1 |
| ≥ 6 to ≤ 17 Y SAE;D1-366 | 1 | NA | 3 | NA |
| ≥6 to ≤ 17 Y At least possibly related SAEs;D1-366 | 0 | NA | 0 | NA |
| ≥ 6 to ≤ 17 Y Deaths;D1-366 | 0 | NA | 0 | NA |
| ≥6 to ≤17 Y Withdrawal from study due to AE;D1-366 | 0 | NA | 0 | NA |
| ≥ 18 Y Any AEs;D1-366 | 157 | 71 | 156 | 72 |
| ≥ 18 Y SAE;D1-366 | 8 | 3 | 7 | 5 |
| ≥ 18 Y At least possibly related SAEs;D1-366 | 0 | 0 | 0 | 0 |
| ≥ 18 Y Deaths;D1-366 | 0 | 0 | 0 | 0 |
| ≥ 18 Y Withdrawal from study due to AE;D1-366 | 0 | 0 | 0 | 0 |
| Overall population ≥ 1 Y Any AEs;D1-366 | 260 | 71 | 280 | 73 |
| Overall population ≥ 1 Y SAE;D1-366 | 12 | 3 | 14 | 5 |
| Overall ≥1Y Atleast possibly related SAEs;D1-366 | 0 | 0 | 0 | 0 |
| Overall population ≥ 1 Y Deaths;D1-366 | 0 | 0 | 0 | 0 |
| Overall population ≥1Y Withdrawal due to AE;D1-366 | 0 | 0 | 0 | 0 |
Immunogenicity was assessed in terms of the Geometric Mean Rabies Virus Neutralizing Antibody (RVNA) Concentration ≥0.5 IU/mL at Days 8, 15, 50,91, 181 and 366 in Adult Subjects, ≥ 18 Years of Age
| IU/mL | 4-sites, 1-week WITH HRIG | 2-sites TRC WITH HRIG |
|---|---|---|
| Day 1 (N= 66, 72) | 0.05 (0.05 to 0.05) | 0.05 (0.05 to 0.05) |
| Day 8 (N= 66, 72) | 0.21 (0.17 to 0.26) | 0.17 (0.14 to 0.21) |
| Day 15 (N= 65, 72) | 13 (11 to 15) | 8.37 (6.96 to 10) |
| Day 50 (N= 65, 69) | 1.97 (1.6 to 2.43) | 6.37 (5.21 to 7.78) |
| Day 91 (N= 65, 72) | 1.01 (0.81 to 1.27) | 2.25 (1.81 to 2.79) |
| Day 181 (N= 65, 71) | 0.88 (0.67 to 1.14) | 1.05 (0.81 to 1.35) |
| Day 366 (N= 65, 69) | 0.68 (0.53 to 0.88) | 0.59 (0.46 to 0.76) |
Immunogenicity was assessed in terms of the number of subjects With Anti-RVNA concentration ≥0.5 IU/mL at Days 8, 15, 50, 91, 181 and 366 in Adult Subjects, ≥ 18 Years of Age
| Percentages of Subjects | 4-sites, 1-week WITH HRIG | 2-sites, TRC WITH HRIG |
|---|---|---|
| Day 1 (N= 66, 72) | 0 (0 to 5) | 0 (0 to 5) |
| Day 8 (N= 66, 72) | 8 (3 to 17) | 10 (4 to 19) |
| Day 15 (N= 65, 72) | 100 (94 to 100) | 99 (93 to 100) |
| Day 50 (N= 65, 69) | 95 (87 to 99) | 100 (95 to 100) |
| Day 91 (N= 65, 72) | 83 (72 to 91) | 99 (93 to 100) |
| Day 181 (N= 65, 71) | 77 (65 to 86) | 85 (74 to 92) |
| Day 366 (N= 65, 69) | 66 (53 to 77) | 70 (57 to 80) |
Collected over Day 1 to day 366 (Study Groups: A1- 4-sites, 1-week" (4-4-4-0-0) ID PEP regimen without HRIG, A2- 4-sites, 1-week" (4-4-4-0-0) ID PEP regimen with HRIG, B1- 2-sites TRC" (2-2-2-0-2) ID PEP regimen without HRIG, B2- 2-sites TRC" (2-2-2-0-2) ID PEP regimen with HRIG).. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| 4-sites, 1-week WITHOUT HRIG | — | 5/356 (1.4%) | 292/356 (82%) |
| 4-sites, 1-week WITH HRIG | — | 1/85 (1.2%) | 78/85 (91.8%) |
| 2-sites, TRC WITHOUT HRIG | — | 4/353 (1.1%) | 298/353 (84.4%) |
| 2-sites, TRC WITH HRIG | — | 2/89 (2.2%) | 82/89 (92.1%) |
| Event | 4-sites, 1-week WITHOUT HRIG | 4-sites, 1-week WITH HRIG | 2-sites, TRC WITHOUT HRIG | 2-sites, TRC WITH HRIG |
|---|---|---|---|---|
| Animal BiteInjury, poisoning and procedural complications | 5/356 | 0/85 | 4/353 | 2/89 |
| Appendiceal AbscessInfections and infestations | 0/356 | 1/85 | 0/353 | 0/89 |
| Dengue FeverInfections and infestations | 1/356 | 1/85 | 1/353 | 0/89 |
| TonsillitisInfections and infestations | 0/356 | 1/85 | 1/353 | 0/89 |
| Angina UnstableCardiac disorders | 0/356 | 0/85 | 0/353 | 1/89 |
| Urinary Tract InfectionInfections and infestations | 0/356 | 0/85 | 0/353 | 1/89 |
| Animal ScratchInjury, poisoning and procedural complications | 1/356 | 0/85 | 2/353 | 1/89 |
| Irritable Bowel SyndromeGastrointestinal disorders | 0/356 | 0/85 | 1/353 | 0/89 |
| GastroenteritisInfections and infestations | 0/356 | 0/85 | 1/353 | 0/89 |
| Hand-Foot-And-Mouth DiseaseInfections and infestations | 0/356 | 0/85 | 1/353 | 0/89 |
| Event | 4-sites, 1-week WITHOUT HRIG | 4-sites, 1-week WITH HRIG | 2-sites, TRC WITHOUT HRIG | 2-sites, TRC WITH HRIG |
|---|---|---|---|---|
| INJECTION SITE ERYTHEMAGeneral disorders | 195/356 | 59/85 | 168/353 | 56/89 |
| HEADACHENervous system disorders | 53/356 | 21/85 | 54/353 | 31/89 |
| FATIGUEGeneral disorders | 53/356 | 16/85 | 52/353 | 24/89 |
| VACCINATION SITE ERYTHEMAGeneral disorders | 82/356 | 19/85 | 79/353 | 23/89 |
| INJECTION SITE PAINGeneral disorders | 77/356 | 18/85 | 89/353 | 20/89 |
| MYALGIAMusculoskeletal and connective tissue disorders | 45/356 | 19/85 | 41/353 | 19/89 |
| ARTHRALGIAMusculoskeletal and connective tissue disorders | 33/356 | 9/85 | 33/353 | 17/89 |
| INJECTION SITE INDURATIONGeneral disorders | 52/356 | 13/85 | 62/353 | 13/89 |
| INJECTION SITE SWELLINGGeneral disorders | 39/356 | 8/85 | 47/353 | 4/89 |
| DIARRHOEAGastrointestinal disorders | 28/356 | 8/85 | 20/353 | 8/89 |
| Age, Continuous(year) | 4-sites, 1-week WITHOUT HRIG | 4-sites, 1-week WITH HRIG | 2-sites, TRC WITHOUT HRIG | 2-sites, TRC WITH HRIG | Total |
|---|---|---|---|---|---|
| Mean | 20.0 ± 15.0 | 32.7 ± 10.8 | 20.6 ± 15.1 | 34.4 ± 11.2 | 22.9 ± 15.3 |
| Sex: Female, Male(Participants) | 4-sites, 1-week WITHOUT HRIG | 4-sites, 1-week WITH HRIG | 2-sites, TRC WITHOUT HRIG | 2-sites, TRC WITH HRIG | Total |
|---|---|---|---|---|---|
| FEMALE | 202 | 44 | 179 | 51 | 476 |
| MALE | 153 | 44 | 175 | 37 | 409 |
The record gives a start of Jun 2014, a primary completion of Oct 2014 and a completion of Aug 2015. It does not say whether these dates are actual or estimated.
Results were first posted in Apr 2017, 2 years 6 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.